13:00 Registration Open
13:30 Welcome remarks
Christina Quensel, CEO of BBB Management GmbH Campus Berlin-Buch
13:45 Stem cell-based treatment and modeling of neuropsychiatric disease
Steven A. Goldman, University of Rochester, Medical Center/ University of Copenhagen, Center for Basic and Translational Neuroscience
14:15 Transformation of a biotech company to a developer of innovative cell-based therapeutics
Kai Pinkernell, Medigene AG
14:30 A clinical Phase I trial of MAGE-A1-specific T cell receptor gene therapy
Elisa Kieback, Max Delbrück Center for Molecular Medicine
14:45 Purification of stable human Treg for improved generation of genetically engineered CAR-Treg
Anna Nowak, Charité / German Rheumatism Research Centre Berlin (DRFZ)
15:00 Expansion of Immunocells for Therapy in a Perfusion Bioreactor System
Dirk Gustavus, Zellwerk GmbH
15:15 Break with Poster session
16:45 Combined ex vivo cell and gene therapy of epidermolysis bullosa by transgenic epidermal stem cells
Michele De Luca, University of Modena, Centre for Regenerative Medicine
17:15 Defining the manufacturing design of an autologous cell-based therapy for cartilage repair to improve its efficacy
Giulietta Roël, co.don AG
17:30 BECAT - a new research cluster for cell and gene therapies
Petra Reinke, Berlin-Brandenburg Center for Regenerative Therapies BCRT
17:45 Goodbye flat biology - the use of 3D cell cultures as pre-clinical models
Christian Regenbrecht, cpo - cellular phenomics & oncology GmbH
18:00 Get-together
Chair: Daniel Besser, German Stem Cell Network (GSCN) c/o Max Delbrück Center for Molecular Medicine (MDC)
The colloquium is organised by Berlin Partner for Business and Technology GmbH, Campus Berlin-Buch, and supported by DECHEMA e.V.
